GFP/Luc Reporter Cell Line - NUGC-4

The NUGC-4 cell line is a well-established human model of gastric cancer, originally derived from a para-aortic lymph node metastasis of a patient with signet-ring cell carcinoma. It is highly valued in gastrointestinal oncology for its aggressive growth profile and its ability to faithfully replicate the complex biology of poorly differentiated, diffuse-type gastric adenocarcinoma. The GFP/Luc Reporter Cell Line - NUGC-4 is a sophisticated, stably transfected derivative explicitly engineered to simultaneously co-express both Green Fluorescent Protein (GFP) and firefly luciferase (Luc). This robust dual-labeling construct ensures continuous, high-level expression of both functional reporter genes across sequential in vitro passages. Crucially, this stable genetic integration is achieved without compromising the fundamental morphological characteristics, the distinct molecular profile, or the intrinsic tumorigenic and metastatic capacity of the original parental NUGC-4 cells.

The incorporation of this dual-reporter system significantly broadens the experimental utility of the NUGC-4 model for comprehensive translational gastric cancer research. For in vitro studies, the distinct GFP expression allows researchers to easily visualize cellular dynamics, accurately quantify rapid proliferation rates, and isolate specific cellular subpopulations using standard fluorescence microscopy and flow cytometry techniques. For in vivo applications, the robust luciferase activity serves as the optimal foundation for non-invasive, longitudinal tracking of tumor progression and metastatic dissemination through bioluminescence imaging (BLI). Because it is a human-derived cell line, the NUGC-4-GFP/Luc model is typically engrafted into immunocompromised mice (such as athymic nude or NSG strains) to establish reliable subcutaneous xenografts, clinically relevant orthotopic gastric tumors, or models of peritoneal carcinomatosis. This specialized reporter line represents an exceptionally valuable platform for evaluating the in vivo therapeutic efficacy of novel chemotherapeutic regimens, targeted pharmacological compounds, and emerging biotherapeutics, facilitating the real-time, accurate quantification of localized tumor burden and disseminated disease in living subjects.